ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Bioresorbable Scaffolds versus Metallic Stents in Routine PCI

Thursday, June 22, 2017

Submitted by

Aristotle Protopapas

Source

Source Name: The New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1614954

Author(s)

Joanna J. Wykrzykowska, Robin P. Kraak, Sjoerd H. Hofma, Rene J. van der Schaaf, E. Karin Arkenbout, Alexander J. IJsselmuiden, Joëlle Elias, Ivo M. van Dongen, Ruben Y.G. Tijssen, Karel T. Koch, Jan Baan, Jr., M. Marije Vis, Robbert J. de Winter, Jan J. Piek, Jan G.P. Tijssen, Jose P.S. Henriques

The Amsterdam Investigator-initiated Absorb Strategy All-comers Trial report safety concerns identified in early results for the bioresorbable scaffold drug eluting stent. The scaffold group experienced significantly higher rates of device thrombosis than the stent group (3.5% vs 0.9%; p<0.001). It seems that no stent, no matter how sophisticated and costly it may be, will ever match arterial coronary bypass in long term outcomes.